TITLE

Osteoporosis drug licensed for women with high fracture risk

AUTHOR(S)
Traynor, Kate
PUB. DATE
July 2010
SOURCE
American Journal of Health-System Pharmacy;7/1/2010, Vol. 67 Issue 13, p1046
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The article reports on the approval of the U.S. Food and Drug Administration (FDA) of Amgen Inc.'s denosumab injection for use in postmenopausal women who have osteoporosis and are at high risk for fracture. In Amgen's study involving 7,808 women, the twice-yearly injection of the drug reduces vertebral fractures by 68%, nonvertebral by 20% and hip fractures by 40%. However, it is stated that patients treated with the drug are at high risk for skin, abdomen, bladder, ear and pericardium infections.
ACCESSION #
51473023

 

Related Articles

  • Amgen: Prolia delay further dampens expectations of hyped drug.  // PharmaWatch: Monthly Review;Dec2009, Vol. 8 Issue 12, p15 

    In this article, the author discusses the delay in the approval of Amgen Inc.'s drug Prolia by U.S. Food and Drug Administration (FDA). FDA has asked for more information regarding the safety of the drug, to be used to cure osteoporosis in older women. He mentions that a similar concern was...

  • Prolia: useful, but not quite revolutionary.  // PharmaWatch: Monthly Review;Jul2010, Vol. 9 Issue 7, p38 

    The article reports on the approval of Amgen Inc.'s Prolia antibody for osteoporosis in post-menopausal women by the Food and Drug Administration (FDA) in the U.S. The FDA released its approval on June 1, 2010 for the company's first-class fully humanized monoclonal antibody Prolia, however, it...

  • New Drug To Tackle Inflammatory Bowel Disease.  // RN;Apr2007, Vol. 70 Issue 4, p62 

    The article reports on the approval of adalimumab as treatment for Crohn's disease by the U.S. Food and Drug Administration (FDA). Adalimumab is a genetically engineered monoclonal antibody that lessens excessive levels of human tumor necrosis factor, which affects the immune response of the...

  • Adalimumab approved for Crohn disease.  // WHO Drug Information;2007, Vol. 21 Issue 2, p114 

    The article informs that Adalimumab, a medicine for treating adult patients with moderate to severe Crohn's disease, has been approved by the U.S. Food and Drug Administration (FDA). It is informed that the use of the drug has been associated with serious infections, such as, tuberculosis,...

  • Amgen's Shares Fall as FDA Seeks Prolia Data.  // Bioworld Week;10/26/2009, Vol. 17 Issue 43, p5 

    The article reports on the reduction of Amgen Inc. shares as the United States Food and Drug Administration (U.S. FDA) gave Prolia drug another rejection. The U.S. FDA asked Amgen to provide more information on the postmarketing safety surveillance study program for Prolia before it will be...

  • Aranesp Cardio Risks May be Greater Than TREAT Reported. Young, Donna // BioWorld Today;10/15/2010, Vol. 21 Issue 200, p1 

    The article reports on the U.S. Food and Drug Administration's (FDA) rejection of the erythropoiesis-stimulating agent (ESA) Aranesp developed by Amgen Inc. According to the FDA, the cardiovascular and renal risks of the drug may be greater than what was earlier reported. The agency said it...

  • Denosumab Receives Conditional Approval from FDA Expert Panel. Elliott, William T. // Neurology Alert;Oct2009 Pharmacology Watch, p2 

    The article reports that a condition approval has been given to Denosumab, a new human monoclonal antibody, by a Food and Drug Administration (FDA) Expert Panel. The agency is testing the drug for treatment of osteoporosis in men and women. The drug would be branded as Proliaâ„¢ by Amgen...

  • Denosumab Receives Conditional Approval from FDA Expert Panel. Elliott, William T. // Infectious Disease Alert;Oct2009 Supplement, p2 

    The article reports on a conditional approval given by the U.S. Food and Drug Administration (FDA) Expert Panel for denosumab, a human monoclonal antibody, for treatment of osteoporosis in men and women. It provides an overview of industry-sponsored studies which suggest that the drug is...

  • Amgen: panitumumab speeding towards approval.  // PharmaWatch: Monthly Review;Jul2006, Vol. 5 Issue 7, p9 

    The article reports on the acceptance of Amgen's biologic license application for panitumumab by Food and Drug Administration and granted it priority review status in the U.S. The biologic license application for panitumumab, Amgen's fully-humanized monoclonal antibody epidermal growth factor...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics